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Abstract: 
Background and purpose:  To evaluate the outcome of malignant salivary gland 
tumours treated with neutron therapy to assess the potential for other high linear 
energy transfer (LET) beams. 
Materials and methods: Neutrons at iThemba LABS are produced by the 
reaction of 66 MeV protons on a beryllium target. A median dose 20.4 Gy, in 12 
fractions in 4 weeks or 15 fractions in 5 weeks, was given to 335 patients with 176 
irresectable, 104 macroscopically residual and 55 unresected tumours. 
Results: Locoregional control was 60.6% at 5 years and 39.1% at 10 years and DSS 
was 66.8% and 53.7% at 5 and 10 years respectively. 
In the univariate analysis T4, >4 cm, high grade, squamous carcinoma, unresected 
and irresectable tumours, and positive nodes were signiﬁcantly worse for LRC. In 
the multivariate analysis tumours >6 cm, squamous carcinoma, irresectable tumours 
and nodes were signiﬁcantly worse for LRC. Tumours >6 cm, high grade, squamous 
carcinoma and nodes were signiﬁcantly worse for DSS. Neither LRC nor DSS was 
inﬂuenced by age, sex, site, dose, fractionation or for initial or recurrent disease. 
Conclusions: Neutron therapy appears to be the treatment of choice for 
macroscopically incompletely excised and irresectable salivary gland tumours with 
improved survival rates. Further improvement may be achieved with other high LET 
modalities with a superior dose proﬁle, such as carbon ions. 
 
The increasing number of hadron therapy centres around the world and their 
use of carbon ion beams have resulted in a growing interest in high-linear energy 
transfer (LET) radiotherapy. Carbon ions combine the advantages of high-LET 
radiation with the superior ballistic properties of charged particles. The most 
commonly used high-LET therapy to date is neutron therapy. The rationale for 
using it for salivary gland tumours is based on Battermann’s observations of 
growth delay of pulmonary metastases treated with neutrons relative to cobalt-
60 radiation [1]. He derived a relative biological effect (RBE) of 8 for fractionated 
therapy to adenoid cystic carcinoma metastases compared with 3 for most normal 
tissues, implying a signiﬁcant therapeutic gain for salivary gland tumours. The 
safe application of high-LET hadron therapy requires biologically driven 
treatment planning that has to be based on clinical data. We contribute to this 
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pool of data by reporting the results of salivary gland tumours treated with 
neutron therapy at iThemba LABS (formerly National Accelerator Centre), South 
Africa, over the last 20 years. 
 
Materials and methods 
iThemba LABS is the only heavy particle therapy facility in the Southern 
Hemisphere. The main accelerator is a 200 MeV separated-sector cyclotron. It 
is the only facility in the world where both high-energy neutrons and high-
energy protons are used for patient treatment and also provides facilities for 
basic and applied research and the production of medical radionuclides. Neutron 
therapy is available on Tuesdays, Wednesdays and Thursdays each week. Most 
patients are referred through one of the two local university teaching hospitals; 
Groote Schuur Hospital (GSH)/University of Cape Town and Tygerberg 
Hospital (TBH)/University of Stellenbosch. 
 
Technical and physical aspects 
The neutron therapy facility incorporates an isocentric gantry – a moving ﬂoor 
permits full rv185° rotation [2]. Variable rectangular ﬁeld sizes between 5.5 x 5.5 
cm2 and 29 x 29 cm2 at a source–axis distance of 150 cm. are available. 
Neutrons are produced by the reaction of 66 MeV protons on a 1.96 cm thick 
beryllium target. Downstream of the target are several beam modiﬁcation 
devices: steel ﬂattening ﬁlters, tungsten wedge ﬁlters and a polyethylene 
hardening ﬁlter. This results in similar depth dose characteristics to an 8 MV X-ray 
beam. A novel 12-cm thick steel post-collimator multiblade trimmer is used for 
conformal ﬁeld shaping [3]. The absorbed doses reported here are the total absorbed 
doses, neutron + photon. The photon component comprises less than 6% and can 
be neglected as the neutron RBE is about 3. 
 
Clinical aspects 
Patients eligible for neutron therapy are those with irresectable tumours, macroscopic 
residual disease after surgery and resectable tumours where the functional status 
associated with resection was considered to be suboptimal. From February 1989 until 
December 2008, 401 patients were treated with curative intent, and they have been 
followed up until 7 February, 2012. This retrospective analysis is conﬁned to 335 
patients with malignant tumours that received a full therapeutic dose to the whole of 
the target volume with neutron therapy only. There were 174 males and 161 females, with 
an age range from 8 to 96 years, median 58 years. Tumour characteristics are shown 
in Table 1. Squamous cell carcinomas of the parotid and submandibular glands were 
included if this appeared to be the primary site. The histology was reviewed by JH. 
Tumours of major salivary glands were classiﬁed according to the 2002 UICC/AJCC 
system. Tumours of minor salivary glands were classiﬁed according to the respective 
sites [4]. 
 
Treatment details 
Patients were CT scanned in an immobilising head cast with 5 mm thick slices at 
increments of 5 mm for 3D planning. Prior to 2000, treatment planning was done 
using a Theraplan planning system at GSH and a General Electric (GE) Target Planning 
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system at TBH. After 2000 an in-house developed treatment planning system, using a 
pencil beam model, was used [5,6]. This system uses VIRTUOS, developed by Deutches 
KrebsForschungZentrum (DKFZ), as a front end for the bulk of the treatment planning 
tasks [7]. Treatment was delivered with source-skin distance (SSD) set-ups until 2000 
and thereafter isocentric set-ups were used. Prior to the introduction of the multiblade 
trimmer in 2000, 12-cm thick tungsten blocks provided the ﬁnal beam shaping. 
 
All neutron doses were prescribed to a minimum tumour dose encompassing the 
planning target volume (PTV). Up until 2002 the majority of patients received a 
median total absorbed dose of 20.4 Gy in 12 fractions, over 4 weeks. For those patients 
who had a delay in completing the prescribed course it was noticed that acute 
morbidity was reduced. Based on this clinical observation together with the results from 
radiobiological experiments in our neutron beam which showed that  there  was  in  fact  
repair  [8], the fractionation schedule was adjusted to 20.4 Gy in 15 fractions over 5 
weeks in 2002. Node positive patients had levels II, III and IV included in the PTV and 
these levels were treated adjunctively, with 14–15 Gy in 3–5 weeks, in 25% of node 
negative patients. The dose to the spinal cord was restricted to 12 Gy to the lateral cord 
and since 1992 the brain dose has been limited to 13 Gy. Complications were scored 
using the RTOG scoring system [9]. 
 
Statistical analysis 
Loco-regional control and disease-speciﬁc survival rates by key variables were 
explored using the Kaplan–Meier life table analysis. Kaplan–Meier graphs are shown to 
10 years of follow-up (this period covers approximately 90% of failures). The log rank 
test was used to evaluate statistical signiﬁcance of differences between curves for 
the full dataset. Hazard Ratios (HR) and their 95% conﬁdence intervals (CI’s) were 
estimated using Cox proportional hazards modelling  to  examine  the  magnitude  of  
associations between variables. All HRs labelled ‘‘crude’’ are adjusted for age in single 
years and sex and are referred to as univariate analyses throughout the text. For 
multivariate analyses, all clinically relevant variables (see Table 2) were included in the 
model. The 95%CI’s for all proportions, rates and HRs are shown in parentheses.  P-
values   were   two-sided   and   considered   signiﬁcant   if p 6 0.05. All analyses were 
performed using Stata software, version 12.1 (Stata Corp LP, 4905 Lakeway Drive, College 
Station, TX 77845, USA). 
 
Results 
Local control and survival 
Local control (LC) is deﬁned as no evidence of clinical or radiological progression of 
disease and loco-regional control (LRC) applies to both the primary and lymph 
nodes. Disease speciﬁc survival (DSS) is deﬁned as death due to disease, loco-
regional, metastases or both. 
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Overall LC was 58.6% (51.1–65.4) at 5 years and 45.9% (36.5– 54.8) at 10 years, and 
LRC was 60.6% (53.0–67.2) at 5 years and 39.1% (30.2–47.9) at 10 years, Fig. 1. The 5- 
and 10-year DSS was 66.8%  (59.8–72.9)  and  53.7%  (44.4–62.2),  and  overall  survival 
(OS) rates were 51% (44.3–57.3) and 37.4% (29.8–44.9) at 5 and 10 years 
respectively, Fig. 1. 
 
Patients who died of disease, 85, had a median follow-up of 19 months (range 1–187 
months); those that died of other causes, 56, had a median follow-up of 14 months 
(range 1–218 months); and those who were last seen alive, 194, had a median follow-
up of 31 months (range 1–257 months). 
 
Salvage surgery was performed on 19 patients with recurrent or progressive disease, 7 
(12.7%) unresected disease, 6 (5.8%) macroscopic residual and 6 (3.4%) irresectable 
disease. 
 
P-values from log rank tests and Cox HR were calculated for each of the variables for 
LC and LRC, and also for DSS and OS. As there was no meaningful difference between 
them, univariate (Crude HR) and multivariate analyses (Adjusted HR) of LRC and DSS 
only are reported, Table 2. 
 
The histological subtypes were grouped into low grade, high grade, adenoid cystic 
carcinoma (ACC) or squamous carcinoma. 
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In the univariate analysis T4, size >4 cm, high grade, squamous carcinoma, unresected 
and irresectable tumours, and positive nodes were signiﬁcantly worse for LRC, Figs. 2 
and 3, and also for DSS with the exception of unresected tumours, Table 2. Salvage 
surgery in 7 (12.7%) of these patients resulted in the DSS approaching those with 
macroscopic residual disease, Fig. 3. 
 
In the multivariate analysis tumours >6 cm, squamous carcinoma, irresectable 
tumours and positive nodes were signiﬁcantly worse for LRC and tumours >6 cm, high 
grade, squamous carcinoma and positive nodes were signiﬁcantly worse for DSS, Table 
2. Neither LRC nor DSS was inﬂuenced signiﬁcantly by age, sex, site, dose,  fractionation  
or  whether  initial  or  recurrent  disease was treated, Table 2. 
 
Nodal disease 
Of the 88 patients with nodes, 9 had neck dissections prior to treatment and in the 
other 79 patients there were 52 with a CR, 25 with stable disease and 2 with 
progressive disease. Fifteen of 247(6%) N0 patients developed nodes; 12 outside the 
treated volume and 3 inside. 
 
 
 
 
Nine died, 8 of loco-regional recurrence (LRR) and 3 with metastases in addition. 
Both LRC and DSS were signiﬁcantly worse in node positive patients but there was no 
signiﬁcant difference whether the nodal status was N1, N2 or N3 classiﬁcation. 
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Distant metastases 
Metastases were present in 19 patients prior to treatment. Ten were alive when last  
seen, from 1 to 79 months, median 27 months, 6 died of metastases, together with 
LRR in 4, 1 died of LRR alone, two died of unknown causes with a clear primary site 
and one was lost to follow-up. Metastases developed in 59 patients; 32 died of 
metastases, with LR progression in 18 of them, 5 died of progressive local disease 
alone, one died of other causes and 21 were alive when last seen, from 11–176 
months, median 44 months. Therefore only 38 of 78 patients, 49%, with metastases 
were known to have died of them, whilst a further 6 patients died of locoregional 
disease. Metastases occurred in 38 patients with ACC (48%), 20 patients with 
adenocarcinoma and 21 other histological subtypes. Of those patients who died 16 
each (34%) were ACC and adenocarcinoma and of those alive when last seen 22 
(69%) had ACC. 
 
Complications 
Late morbidity, greater than Grade 2, was seen in 30 patients; 13 patients Grade 3, 16 
Grade 4 and 1 Grade 5. Five patients had 2 complications in which case the highest 
was reported. There were 3 cases of brain necrosis, 2 Grade 4 and one Grade 5 
occurring in patients treated prior to 1992. One Grade 4 patient was treated 
successfully with surgery; the other died, either of necrosis or metastases. No 
incidence of CNS morbidity occurred with the brain dose limited to 13 Gy. There was no 
incidence of spinal cord damage. Of the 14 other patients with Grade 4 morbidity there 
were 11 bone necroses, (4 of which had bone invasion initially) with or without 
overlying skin or mucosal ulceration, 2 skin ulcers and one mucosal ulcer. The 13 
Grade 3 complications included 9 with severe xerostomia, 3 with severe 
subcutaneous induration and one recurrent ear infection. 
 
The overall number of complications was 30 in 12218.5 pm giving a complication rate 
of 2.4 (1.7–3.5). Grade 3 and 4 complications were analysed in relation to dose and 
fractionation. There were 2 complications in 950.5 pm in the 18–20 Gy group and 28 
in 11468.9 pm in the >20 Gy group, giving complication rates of 2.1(0.5–8.5) and 
2.5(1.7–3.6), respectively. There were 25 complications in 7749.4 pm in the 12 
fractions in 4 weeks group, 3 in 1608.3 pm  in  the  12  fractions  in  >4 weeks  group  
and  2  in 2795.9 pm in the 15 fractions in 5 weeks group, giving complication rates of 
3.2 (2.2–4.8), 1.9 (0.6–5.8) and 0.7 (0.2–2.9) respectively. These were not 
statistically signiﬁcant. The probability of developing complications is shown in Fig. 4. 
 
Discussion 
High-LET neutron therapy has several radiobiological advantages over low-LET 
radiation due to the increased energy deposition per unit length of track [10]. It has a low 
oxygen enhancement ratio (OER), a reduction in variation of sensitivity around the cell 
cycle and a decreased ability of tumour cells to repair sublethal and potentially lethal 
damage. Advanced salivary gland tumours are large and may contain a signiﬁcant 
number of hypoxic cells which are relatively resistant to low-LET radiation. They also 
tend to be slow growing with a large proportion of cells in the resting phase of the cell 
cycle where they may be protected from the full effects of low-LET radiation. They 
https://repository.uwc.ac.za/
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should thus respond well to high-LET irradiation. Treatment with conventional 
radiation alone has not been very satisfactory, with a combined overall local control 
rate of 26% in 299 patients [11]. More recently, Chen showed 5-year and 10-year local 
control rates of 70% and 57% respectively but only 58% and 39% respectively for T3/4 
tumours [12]; Mendenhall had a 10-year local control rate of 42% but this was only 21% 
for T4 tumours [13]; Terhaard showed a 5-year local control rate of 50% provided they 
received P66 Gy [14]. Accelerated hyperfractionated radiation was investigated by Wang 
and Goodman giving  a median dose of 68.2 Gy and produced local control rates of 
100% for 9 parotid tumours and 78% for 15 minor salivary gland tumours [15]. 
 
The combined overall local control rate for advanced salivary gland tumours treated 
with fast neutron therapy was 67% in 309 patients [11], and the randomised 
RTOG/MRC clinical trial conﬁrmed the superiority of neutron therapy for local 
control compared to photons [16]. Subsequent results from Seattle have shown a 
59% LRC rate and 67% cause speciﬁc survival (CSS) at 6 years [17] and 76.5% LC and 
68.2% CSS at 7 years in major salivary gland tumours, the majority of which had 
macroscopically resected disease [18]. Huber has shown a 75% 5-year LCR rate for 
advanced adenoid cystic carcinomas [19]. 
 
Our results show a similar LC probability and DSS despite more irresectable disease. The 
survival rate is much higher than the RTOG/MRC trial. Thirty-one patients were still 
alive with metastatic disease when last seen. Most salivary gland tumours are slow 
growing as are the metastases, particularly of adenoid cystic carcinomas, and the 
presence of metastases when ﬁrst seen should not preclude radical treatment for the 
primary tumour. Neutron therapy was effective in controlling nodal disease but its 
presence affected both LRC and survival adversely. 
 
The incidence of severe late toxicity, Grades 3 and 4, is 30 in 335 patients (8.9%) or 11.1% 
at 6 years, Fig. 4, which is not excessive. Huber found in his comparison of neutron 
therapy versus mixed beam versus photon therapy that although the complication rates 
were higher with neutron therapy, 5 of 27 (17%) versus 2 of 21 (10%) versus 1 of 
25(4%) respectively, this  was  not  signiﬁcant [19]. Douglas had a 6 year actuarial Grade 
3 and 4 toxicity of 10% [17]. There was no signiﬁcant difference in complication rates 
between the different dose and fractionation groups. 
 
Intensity modulated RT (IMRT) has the potential to treat with less morbidity but this 
was not borne out in the one series treating 25 patients with adenoid cystic carcinomas 
[20]. A median dose of 66 Gy was given to the CTV. Local control rate was 38% at 3 
years and PFS 48%. Neutron IMRT is theoretically possible but has not been  used  
clinically  to  date.  Very  promising  results  have  been achieved treating skull base 
adenoid cystic carcinomas with protons and photons to a median combined dose of 
76 Gy. LC was 93% at 5 years and 82% at 10 years, although the disease free survival 
was 56% at 5 years [21]. There were, however, 10 Grade 3 and 2 Grade 5 brain 
toxicities in 23 patients. Neither of these modalities has the advantages of high-LET 
radiation. 
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Carbon ions offer the best of both worlds with their excellent dose distribution 
proﬁle and similar radiobiological advantages to neutrons and early results are 
available from the Heavy Ion Medical Accelerator in Chiba, Japan (HIMAC) and 
Heidelberg, Germany. Local control of advanced head and neck tumours treated in a 
phase II trial with carbon ions was 73% at 5 years for both adenoid cystic carcinomas 
and adenocarcinomas and late morbidity did not exceed Grade 2 [22]. In another 
phase I/II trial locally advanced adenoid cystic carcinomas were treated with 
fractionated stereotactic RT or IMRT to 54 Gy and a carbon ion boost of 18 
Gy(RBE). LRC probability was 77.5% at 4 years also with minimal morbidity [23]. 
 
As there are few centres offering neutron therapy and taking into account the rarity of 
salivary gland tumours, it is unlikely that any other trials will be conducted. We 
therefore have to rely on retrospective studies to assess the value of neutron therapy 
for these tumors. The results are very promising for advanced disease and neutron beam 
therapy should still be offered where available. Salivary gland tumours are a good 
indication for heavy charged particles and based on the neutron therapy response they 
would be an ideal pathology to investigate the value of high LET radiation. An 
internationally collaborative study comparing protons with carbon ions would address 
the question of whether high LET radiation is intrinsically  better for  salivary gland 
tumours; an important question in the light of the super high cost of carbon ion 
facilities [24]. 
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